Beam Therapeutics: Una valoración con potencial alcista (NASDAQ:BEAM)
· seekingalpha.com
Perspectivas de las acciones de Beam Therapeutics (BEAM): cartera de edición genética, sólida liquidez hasta 2029 y valoración conservadora.
Max is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies. His investment approach is fundamenta...